|
Diabetes Care, Vol 18, Issue 2 226-233, Copyright © 1995 by American Diabetes Association
Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men
C Ferri, A Carlomagno, S Coassin, R Baldoncini, MR Cassone Faldetta, O Laurenti, G Properzi, A Santucci and G De Mattia
Istituto di I Clinica Medica, Universita La Sapienza, Rome, Italy.
OBJECTIVE--To evaluate whether or not insulin stimulates endothelin (ET)-1
secretion in vivo. RESEARCH DESIGN AND METHODS--Plasma ET-1 levels were
evaluated in 16 lean normotensive men with non-insulin-dependent diabetes
mellitus (NIDDM) (mean age 50.3 +/- 4.1 years) during either a 2-h
euglycemic hyperinsulinemic clamp (40 mU insulin.m-2.min-1) or placebo
infusion (50 ml isotonic saline) according to a single-blind randomized
crossover protocol. RESULTS--Circulating ET-1 levels increased during the
euglycemic hyperinsulinemic clamp (from 0.88 +/- 0.38 pg/ml at time 0 to
1.66 +/- 0.22 pg/ml and 1.89 +/- 0.99 pg/ml at 60 and 120 min, respectively
[P < 0.05 vs. time 0]) and returned to baseline levels after the
discontinuation of insulin infusion (0.71 +/- 0.22 pg/ml after a 30-min
period of recovery [NS]). Compared with placebo, the euglycemic
hyperinsulinemic clamp induced a significant increase in plasma ET-1 levels
at 60 min (P < 0.0001) and 120 min (P < 0.0001). Changes in basal
insulin levels and corresponding changes in circulating ET-1 levels after a
2-h euglycemic hyperinsulinemic clamp were significantly correlated (r =
0.771, P < 0.0001). A possible unfavorable effect of ET-1 on the tissue
sensitivity to insulin-stimulated glucose uptake was suggested by the
presence of a negative correlation between total glucose uptake and
baseline ET-1 levels (r = -0.498, P < 0.05). CONCLUSIONS--Our findings
indicate that circulating ET-1 levels significantly increase during
euglycemic hyperinsulinemic clamp in men with NIDDM. The negative
correlation between total glucose uptake and circulating ET-1 levels
suggests that the peptide might exert negative effects on the insulin
sensitivity of target tissues. The consequent increase in insulin secretion
as well as the insulin-related ET-1 release from endothelial cells could
favor the development of diabetes-related vascular lesions.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. G. Clark
Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle
Am J Physiol Endocrinol Metab,
October 1, 2008;
295(4):
E732 - E750.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Eringa, C. D. A. Stehouwer, M. H. Roos, N. Westerhof, and P. Sipkema
Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats
Am J Physiol Endocrinol Metab,
November 1, 2007;
293(5):
E1134 - E1139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev.,
August 1, 2007;
28(5):
463 - 491.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ahlborg, A. Shemyakin, F. Bohm, A. Gonon, and J. Pernow
Dual Endothelin Receptor Blockade Acutely Improves Insulin Sensitivity in Obese Patients With Insulin Resistance and Coronary Artery Disease
Diabetes Care,
March 1, 2007;
30(3):
591 - 596.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Sarafidis and G. L. Bakris
Insulin and Endothelin: An Interplay Contributing to Hypertension Development?
J. Clin. Endocrinol. Metab.,
February 1, 2007;
92(2):
379 - 385.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kelly, T. Ruane-O'Hora, M. I. M. Noble, A. J. Drake-Holland, and H. M. Snow
Differential inhibition by hyperglycaemia of shear stress- but not acetylcholine-mediated dilatation in the iliac artery of the anaesthetized pig
J. Physiol.,
May 15, 2006;
573(1):
133 - 145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Hermann, W. Li, H. Dominguez, N. Ihlemann, C. Rask-Madsen, A. Major-Pedersen, D. B. Nielsen, K. W. Hansen, M. Hawkins, L. Kober, et al.
Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
March 1, 2006;
91(3):
1001 - 1008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Eringa, C. D. A. Stehouwer, K. Walburg, A. D. Clark, G. P. van Nieuw Amerongen, N. Westerhof, and P. Sipkema
Physiological Concentrations of Insulin Induce Endothelin-Dependent Vasoconstriction of Skeletal Muscle Resistance Arteries in the Presence of Tumor Necrosis Factor-{alpha} Dependence on c-Jun N-Terminal Kinase
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2006;
26(2):
274 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Eringa, C. D. A. Stehouwer, G. P. van Nieuw Amerongen, L. Ouwehand, N. Westerhof, and P. Sipkema
Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium
Am J Physiol Heart Circ Physiol,
November 1, 2004;
287(5):
H2043 - H2048.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rab, S. Dallinger, K. Polak, J. Pleiner, E. Polska, M. Wolzt, and L. Schmetterer
Specific Endothelin ETA Receptor Antagonism Does Not Modulate Insulin-Induced Hemodynamic Effects in the Human Kidney, Eye, or Forearm
J. Pharmacol. Exp. Ther.,
May 1, 2004;
309(2):
692 - 696.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tardif, N. Julien, A. Pelletier, G. Thibault, A. K. Srivastava, J.-L. Chiasson, and L. Coderre
Chronic exposure to beta -hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes
Am J Physiol Endocrinol Metab,
December 1, 2001;
281(6):
E1205 - E1212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis
Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy
J. Clin. Endocrinol. Metab.,
October 1, 2001;
86(10):
4666 - 4673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.J. Irving, J.P. Noon, G.C.M. Watt, D.J. Webb, and B.R. Walker
Activation of the endothelin system in insulin resistance
QJM,
June 1, 2001;
94(6):
321 - 326.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Calles-Escandon and M. Cipolla
Diabetes and Endothelial Dysfunction: A Clinical Perspective
Endocr. Rev.,
February 1, 2001;
22(1):
36 - 52.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
G. Desideri, A. Gaspardone, M. Gentile, A. Santucci, P. A. Gioffre, and C. Ferri
Endothelial Activation in Patients With Cardiac Syndrome X
Circulation,
November 7, 2000;
102(19):
2359 - 2364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ferri, C. Bellini, G. Desideri, E. Giuliani, L. De Siati, S. Cicogna, and A. Santucci
Clustering of Endothelial Markers of Vascular Damage in Human Salt-Sensitive Hypertension : Influence of Dietary Sodium Load and Depletion
Hypertension,
November 1, 1998;
32(5):
862 - 868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J Rabelink, E. S.G Stroes, K.P. Bouter, and P. Morrison
Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
Cardiovasc Res,
September 1, 1998;
39(3):
543 - 549.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Nava Maria, T. Collados, F. Masso, and V. Guarner
Endothelin Mediation of Insulin and Glucose-Induced Changes in Vascular Contractility
Hypertension,
October 1, 1997;
30(4):
825 - 829.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
Z. K. Krowicki, N. A. Nathan, and P. J. Hornby
Excitatory Gastric Motor and Cardiovascular Effects of Endothelins in the Dorsal Vagal Complex are Mediated Through ETA Receptors
J. Pharmacol. Exp. Ther.,
August 1, 1997;
282(2):
535 - 542.
[Abstract]
[Full Text]
|
 |
|
Copyright © 1995 by the American Diabetes Association.
|
|
| |
|